Journal of Industrial Technology (산업기술연구)

Kangwon National University, Institute of Industrial Technology (강원대학교 산업기술연구소)
권호 표지
DOI QR코드

DOI QR Code

Biomedical Application of Gene Editing

유전자 교정 기술의 생의학적 응용

  • Ju-Chan, Park (College of Pharmacy, Seoul National University) ;
  • Hyeon-Ki, Jang (Division of Chemical Engineering and Bioengineering, College of Art Culture and Engineering)
  • Received : 2022.11.09
  • Accepted : 2022.12.14
  • Published : 2022.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The CRISPR system has revolutionized gene editing field. Cas9-mediated gene editing such as Indel induction or HDR enable targeted gene disruption or precise correction of mutation. Moreover, CRISPR-based new editing tools have been developed such as base editors. In this review, we focus on gene editing in human pluripotent stem cells, which is principal technique for gene correction therapy and disease modeling. Pluripotent stem cell-specific drug YM155 enabled selection of target gene-edited pluripotent stem cells. Also, we discussed base editing for treatment of congenital retina disease. Adenine base editor delivery as RNP form provide an approach for genetic disease treatment with safe and precise in vivo gene correction.

Keywords

Acknowledgement

이 논문은 2022년도 한국연구재단의 기초연구사업의 지원을 받아 수행된 연구임(No. NRF-2022R1C1C2011617). 본문에 삽입된 그림은 BioRender.Com을 이용하여 작성되었음.

References

  1. Hsu, Patrick D., Lander, Eric S.,Zhang, F., 2014, Development and Applications of CRISPR-Cas9 for Genome Engineering, Cell 157:6 1262-1278. https://doi.org/10.1016/j.cell.2014.05.010
  2. Jang, H. K., Song, B., Hwang, G. H.,Bae, S., 2020, Current trends in gene recovery mediated by the CRISPR-Cas system, Exp Mol Med 52:7 1016-1027.
  3. Ihry, R. J., Worringer, K. A., Salick, M. R., Frias, E., Ho, D., Theriault, K., Kommineni, S., Chen, J., Sondey, M., Ye, C., Randhawa, R., Kulkarni, T., Yang, Z., McAllister, G., Russ, C., Reece-Hoyes, J., Forrester, W., Hoffman, G. R., Dolmetsch, R.,Kaykas, A., 2018, p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells, Nat Med 24:7 939-946. https://doi.org/10.1038/s41591-018-0050-6
  4. Haapaniemi, E., Botla, S., Persson, J., Schmierer, B.,Taipale, J., 2018, CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response, Nat Med 24:7 927-930. https://doi.org/10.1038/s41591-018-0049-z
  5. Shin, H. Y., Wang, C., Lee, H. K., Yoo, K. H., Zeng, X., Kuhns, T., Yang, C. M., Mohr, T., Liu, C.,Hennighausen, L., 2017, CRISPR/Cas9 targeting events cause complex deletions and insertions at 17 sites in the mouse genome, Nat Commun 8 15464. https://doi.org/10.1038/ncomms15464
  6. Kosicki, M., Tomberg, K.,Bradley, A., 2018, Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements, Nat Biotechnol 36:8 765-771. https://doi.org/10.1038/nbt.4192
  7. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A.,Liu, D. R., 2016, Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage, Nature 533:7603 420-424. https://doi.org/10.1038/nature17946
  8. Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I.,Liu, D. R., 2017, Programmable base editing of AT to GC in genomic DNA without DNA cleavage, Nature 551:7681 464-471. https://doi.org/10.1038/nature24644
  9. Dutta, D., Heo, I.,Clevers, H., 2017, Disease Modeling in Stem Cell-Derived 3D Organoid Systems, Trends Mol Med 23:5 393-410. https://doi.org/10.1016/j.molmed.2017.02.007
  10. Yamanaka, S., 2020, Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges, Cell Stem Cell 27:4 523-531. https://doi.org/10.1016/j.stem.2020.09.014
  11. Rowe, R. G.,Daley, G. Q., 2019, Induced pluripotent stem cells in disease modelling and drug discovery, Nat Rev Genet 20:7 377-388. https://doi.org/10.1038/s41576-019-0100-z
  12. Wang, H. X., Li, M., Lee, C. M., Chakraborty, S., Kim, H. W., Bao, G.,Leong, K. W., 2017, CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery, Chem Rev 117:15 9874-9906. https://doi.org/10.1021/acs.chemrev.6b00799
  13. Sebastiano, V., Zhen, H. H., Haddad, B., Bashkirova, E., Melo, S. P., Wang, P., Leung, T. L., Siprashvili, Z., Tichy, A., Li, J., Ameen, M., Hawkins, J., Lee, S., Li, L., Schwertschkow, A., Bauer, G., Lisowski, L., Kay, M. A., Kim, S. K., Lane, A. T., Wernig, M.,Oro, A. E., 2014, Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa, Sci Transl Med 6:264 264ra163.
  14. Niu, X., He, W., Song, B., Ou, Z., Fan, D., Chen, Y., Fan, Y.,Sun, X., 2016, Combining Single Strand Oligodeoxynucleotides and CRISPR/Cas9 to Correct Gene Mutations in β-Thalassemia-induced Pluripotent Stem Cells, J Biol Chem 291:32 16576-16585. https://doi.org/10.1074/jbc.M116.719237
  15. Ortiz-Virumbrales, M., Moreno, C. L., Kruglikov, I., Marazuela, P., Sproul, A., Jacob, S., Zimmer, M., Paull, D., Zhang, B., Schadt, E. E., Ehrlich, M. E., Tanzi, R. E., Arancio, O., Noggle, S.,Gandy, S., 2017, CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2 (N141I) neurons, Acta Neuropathol Commun 5:1 77. https://doi.org/10.1186/s40478-017-0475-z
  16. Steyer, B., Bu, Q., Cory, E., Jiang, K., Duong, S., Sinha, D., Steltzer, S., Gamm, D., Chang, Q.,Saha, K., 2018, Scarless Genome Editing of Human Pluripotent Stem Cells via Transient Puromycin Selection, Stem Cell Reports 10:2 642-654. https://doi.org/10.1016/j.stemcr.2017.12.004
  17. Li, X. L., Li, G. H., Fu, J., Fu, Y. W., Zhang, L., Chen, W., Arakaki, C., Zhang, J. P., Wen, W., Zhao, M., Chen, W. V., Botimer, G. D., Baylink, D., Aranda, L., Choi, H., Bechar, R., Talbot, P., Sun, C. K., Cheng, T.,Zhang, X. B., 2018, Highly efficient genome editing via CRISPR-Cas9 in human pluripotent stem cells is achieved by transient BCL-XL overexpression, Nucleic Acids Res 46:19 10195-10215.
  18. Shahryari, A., Moya, N., Siehler, J., Wang, X., Burtscher, I.,Lickert, H., 2021, Increasing Gene Editing Efficiency for CRISPR-Cas9 by Small RNAs in Pluripotent Stem Cells, Crispr j 4:4 491-501. https://doi.org/10.1089/crispr.2021.0014
  19. Howden, S. E., McColl, B., Glaser, A., Vadolas, J., Petrou, S., Little, M. H., Elefanty, A. G.,Stanley, E. G., 2016, A Cas9 Variant for Efficient Generation of Indel-Free Knockin or Gene-Corrected Human Pluripotent Stem Cells, Stem Cell Reports 7:3 508-517. https://doi.org/10.1016/j.stemcr.2016.07.001
  20. Yang, D., Scavuzzo, M. A., Chmielowiec, J., Sharp, R., Bajic, A.,Borowiak, M., 2016, Enrichment of G2/M cell cycle phase in human pluripotent stem cells enhances HDR-mediated gene repair with customizable endonucleases, Sci Rep 6 21264. https://doi.org/10.1038/srep21264
  21. Riesenberg, S.,Maricic, T., 2018, Targeting repair pathways with small molecules increases precise genome editing in pluripotent stem cells, Nat Commun 9:1 2164. https://doi.org/10.1038/s41467-018-04609-7
  22. Martin, R. M., Ikeda, K., Cromer, M. K., Uchida, N., Nishimura, T., Romano, R., Tong, A. J., Lemgart, V. T., Camarena, J., Pavel-Dinu, M., Sindhu, C., Wiebking, V., Vaidyanathan, S., Dever, D. P., Bak, R. O., Laustsen, A., Lesch, B. J., Jakobsen, M. R., Sebastiano, V., Nakauchi, H.,Porteus, M. H., 2019, Highly Efficient and Marker-free Genome Editing of Human Pluripotent Stem Cells by CRISPR-Cas9 RNP and AAV6 Donor-Mediated Homologous Recombination, Cell Stem Cell 24:5 821-828.e825. https://doi.org/10.1016/j.stem.2019.04.001
  23. Kim, K. T., Park, J. C., Jang, H. K., Lee, H., Park, S., Kim, J., Kwon, O. S., Go, Y. H., Jin, Y., Kim, W., Lee, J., Bae, S.,Cha, H. J., 2020, Safe scarless cassette-free selection of genome-edited human pluripotent stem cells using temporary drug resistance, Biomaterials 262 120295. https://doi.org/10.1016/j.biomaterials.2020.120295
  24. Lee, M. O., Moon, S. H., Jeong, H. C., Yi, J. Y., Lee, T. H., Shim, S. H., Rhee, Y. H., Lee, S. H., Oh, S. J., Lee, M. Y., Han, M. J., Cho, Y. S., Chung, H. M., Kim, K. S.,Cha, H. J., 2013, Inhibition of pluripotent stem cell-derived teratoma formation by small molecules, Proc Natl Acad Sci U S A 110:35 E3281-3290.
  25. Kim, K. T., Jeong, H. C., Kim, C. Y., Kim, E. Y., Heo, S. H., Cho, S. J., Hong, K. S.,Cha, H. J., 2017, Intact wound repair activity of human mesenchymal stem cells after YM155 mediated selective ablation of undifferentiated human embryonic stem cells, J Dermatol Sci 86:2 123-131.
  26. Rees, H. A.,Liu, D. R., 2018, Base editing: precision chemistry on the genome and transcriptome ofliving cells, Nature Reviews Genetics 19:12 770-788. https://doi.org/10.1038/s41576-018-0059-1
  27. Song, M., Kim, H. K., Lee, S., Kim, Y., Seo, S.-Y., Park, J., Choi, J. W., Jang, H., Shin, J. H., Min, S., Quan, Z., Kim, J. H., Kang, H. C., Yoon, S.,Kim, H. H., 2020, Sequence-specific prediction of the efficiencies of adenine and cytosine base editors, Nature Biotechnology 38:9 1037-1043.
  28. Park, J. C., Jang, H. K., Kim, J., Han, J. H., Jung, Y., Kim, K., Bae, S.,Cha, H. J., 2022, High expression of uracil DNA glycosylase determines C to T substitution in human pluripotent stem cells, Mol Ther Nucleic Acids 27 175-183. https://doi.org/10.1016/j.omtn.2021.11.023
  29. Komor, A. C., Zhao, K. T., Packer, M. S., Gaudelli, N. M., Waterbury, A. L., Koblan, L. W., Kim, Y. B., Badran, A. H.,Liu, D. R., 2017, Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity, Sci Adv 3:8 eaao4774. https://doi.org/10.1126/sciadv.aao4774
  30. Park, J. C., Kim, J., Jang, H. K., Lee, S. Y., Kim, K. T., Kwon, E. J., Park, S., Lee, H. S., Choi, H., Park, S. Y., Choi, H. J., Park, S. J., Moon, S. H., Bae, S.,Cha, H. J., 2022, Multiple isogenic GNE-myopathy modeling with mutation specific phenotypes from human pluripotent stem cells by base editors, Biomaterials 282 121419. https://doi.org/10.1016/j.biomaterials.2022.121419
  31. Truong, D. J., Kuhner, K., Kuhn, R., Werfel, S., Engelhardt, S., Wurst, W.,Ortiz, O., 2015, Development of an intein-mediated split-Cas9 system for gene therapy, Nucleic Acids Res 43:13 6450-6458. https://doi.org/10.1093/nar/gkv601
  32. Chen, Y., Zhi, S., Liu, W., Wen, J., Hu, S., Cao, T., Sun, H., Li, Y., Huang, L., Liu, Y., Liang, P.,Huang, J., 2020, Development of Highly Efficient Dual-AAV Split Adenosine Base Editor for In Vivo Gene Therapy, Small Methods 4:9 2000309. https://doi.org/10.1002/smtd.202000309
  33. Keeler, A. M.,Flotte, T. R., 2019, Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?, Annu Rev Virol 6:1 601-621.
  34. Jo, D. H., Jang, H.-K., Cho, C. S., Han, J. H., Ryu, G., Jung, Y., Bae, S.,Kim, J. H., 2021, Therapeutic adenine base editing corrects nonsense mutation and improves visual function in a mouse model of Leber congenital amaurosis, bioRxiv 2021.2001.2007.425822.
  35. Raguram, A., Banskota, S.,Liu, D. R., 2022, Therapeutic invivo delivery of gene editing agents, Cell 185:15 2806-2827. https://doi.org/10.1016/j.cell.2022.03.045
  36. Jang, H. K., Jo, D. H., Lee, S. N., Cho, C. S., Jeong, Y. K., Jung, Y., Yu, J., Kim, J. H., Woo, J. S.,Bae, S., 2021, High-purity production and precise editing of DNA base editing ribonucleoproteins, Sci Adv 7:35.
  37. Nahmad, A. D., Reuveni, E., Goldschmidt, E., Tenne, T., Liberman, M., Horovitz-Fried, M., Khosravi, R., Kobo, H., Reinstein, E., Madi, A., Ben-David, U.,Barzel, A., 2022, Frequent aneuploidy in primary human T cells after CRISPRCas9 cleavage, Nature Biotechnology.
  38. Slesarenko, Y. S., Lavrov, A. V.,Smirnikhina, S. A., 2022, Off-target effects of base editors: what we know and how we can reduce it, Curr Genet 68:1 39-48. https://doi.org/10.1007/s00294-021-01211-1
  39. Richter, M. F., Zhao, K. T., Eton, E., Lapinaite, A., Newby, G. A., Thuronyi, B. W., Wilson, C., Koblan, L. W., Zeng, J., Bauer, D. E., Doudna, J. A.,Liu, D. R., 2020, Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity, Nature Biotechnology 38:7 883-891. https://doi.org/10.1038/s41587-020-0453-z
  40. Li, S., Yuan, B., Cao, J., Chen, J., Chen, J., Qiu, J., Zhao, X.-M., Wang, X., Qiu, Z.,Cheng, T.-L., 2020, Docking sites inside Cas9 for adenine base editing diversification and RNA off-target elimination, Nature Communications 11:1 5827. https://doi.org/10.1038/s41467-020-19730-9
  41. Paunovska, K., Loughrey, D.,Dahlman, J. E., 2022, Drug delivery systems for RNA therapeutics, Nature Reviews Genetics 23:5 265-280. https://doi.org/10.1038/s41576-021-00439-4
  42. Musunuru, K., Chadwick, A. C., Mizoguchi, T., Garcia, S. P., DeNizio, J. E., Reiss, C. W., Wang, K., Iyer, S., Dutta, C., Clendaniel, V., Amaonye, M., Beach, A., Berth, K., Biswas, S., Braun, M. C., Chen, H.-M., Colace, T. V., Ganey, J. D., Gangopadhyay, S. A., Garrity, R., Kasiewicz, L. N., Lavoie, J., Madsen, J. A., Matsumoto, Y., Mazzola, A. M., Nasrullah, Y. S., Nneji, J., Ren, H., Sanjeev, A., Shay, M., Stahley, M. R., Fan, S. H. Y., Tam, Y. K., Gaudelli, N. M., Ciaramella, G., Stolz, L. E., Malyala, P., Cheng, C. J., Rajeev, K. G., Rohde, E., Bellinger, A. M.,Kathiresan, S., 2021, In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates, Nature 593:7859 429-434.
  43. Rothgangl, T., Dennis, M. K., Lin, P. J. C., Oka, R., Witzigmann, D., Villiger, L., Qi, W., Hruzova, M., Kissling, L., Lenggenhager, D., Borrelli, C., Egli, S., Frey, N., Bakker, N., Walker, J. A., Kadina, A. P., Victorov, D. V., Pacesa, M., Kreutzer, S., Kontarakis, Z., Moor, A., Jinek, M., Weissman, D., Stoffel, M., van Boxtel, R., Holden, K., Pardi, N., Thony, B., Haberle, J., Tam, Y. K., Semple, S. C.,Schwank, G., 2021, In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels, Nature Biotechnology 39:8 949-957. https://doi.org/10.1038/s41587-021-00933-4
  44. Yeh, W.-H., Chiang, H., Rees, H. A., Edge, A. S. B.,Liu, D. R., 2018, In vivo base editing of post-mitotic sensory cells, Nature Communications 9:1 2184.
  45. Banskota, S., Raguram, A., Suh, S., Du, S. W., Davis, J. R., Choi, E. H., Wang, X., Nielsen, S. C., Newby, G. A., Randolph, P. B., Osborn, M. J., Musunuru, K., Palczewski, K.,Liu, D. R., 2022, Engineered virus-like particles for efficient invivo delivery of therapeutic proteins, Cell 185:2 250-265.e216.